# Who are Fujifilm Holdings's customers? Who does Fujifilm Holdings earn revenue from?
Canonical: https://valuechain.wiki/fujifilm-holdings · Facet: customers · Updated: 2026-09-23T09:58:34.474511+00:00 · Source: ValueChain.wiki (cited money-flow graph)

**Citable summary**: Fujifilm Holdings's confirmed revenue counterparties include Regeneron Pharmaceuticals (바이오 CDMO), Biogen Inc. plus 2 undisclosed/aggregate relationships. Per the valuechain.wiki graph: 4 revenue edges, backed by 9 dated sources, 1 of them primary filings (as of 2026-09-23).

### 반도체 제조사 (레지스트·CMP 슬러리) (high)
- metric: Amount ¥170B · FY24~26 투자 · semiconductor materials growth investment
- note: Core Electronics-segment revenue. Fujifilm supplies photoresists (ArF immersion, 28nm node verified with imec, world No.5 share) and CMP slurries (advanced-packaging product launched, targeting global No.1 in total CMP slurry by FY2030) to semiconductor makers. Generative-AI advanced-chip demand lifted Electronic Materials revenue 29.3% YoY and the segment to JPY432.8B, up 20.7%. JPY170B growth investment in semiconductor materials across FY24-26.
- [mentions] Yahoo Finance (EN, news, published 2026-05-01) https://finance.yahoo.com/quote/4901.T/analyst-insights/: "Analyst consensus 'Buy' (10 of 14 buy), average target JPY4,138; Morgan Stanley Overweight at JPY4,100, reflecting semiconductor-materials and bio-CDMO growth."
- [confirms] FUJIFILM (EN, ir, published 2026-04-01) https://www.fujifilm.com/jp/en/news/hq/12973: "Launched CMP slurry for advanced packaging; aims for No.1 global share of total CMP slurry market by FY2030."
- [confirms] Global Economic (KO, news, published 2025-11-10) https://www.g-enews.com/article/Global-Biz/2025/11/202511101225542908e7e8286d56_1: "Q2 semiconductor (electronic materials) revenue rose 11.9% YoY; H1 hit record results."
- [confirms] FUJIFILM (EN, ir, published 2025-06-01) https://www.fujifilm.com/jp/en/news/hq/12078: "Growth investment in semiconductor materials including CMP slurry capacity expansion at the Kumamoto site."
- [confirms] FUJIFILM Holdings (EN, filing, published 2025-05-02) https://ir.fujifilm.com/en/investors/ir-news/auto_20250502530287/pdfFile.pdf: "Electronics segment revenue JPY432.8B (+20.7%); Electronic Materials revenue increased 29.3% YoY, driven by strong demand for advanced semiconductor materials used in generative AI."

### Regeneron Pharmaceuticals (바이오 CDMO) (high)  → /regeneron-pharmaceuticals.md
- metric: contract $3B · 10년(2025~) · Diosynth 10-year manufacturing agreement
- note: Subsidiary Diosynth's 10-year, $3B+ US manufacturing agreement with Regeneron — the anchor deal for Healthcare bio-CDMO growth, producing antibodies at the new Holly Springs plant ($3.2B).
- [confirms] FUJIFILM Diosynth Biotechnologies (EN, ir, published 2025-04-22) https://www.fujifilm.com/us/en/news/biotechnology/fujifilm-diosynth-biotechnologies-and-regeneron-sign-a-10-year-us-manufacturing-agreement-valued-at-over-3-billion: "FUJIFILM Diosynth Biotechnologies and Regeneron signed a 10-year U.S. manufacturing agreement valued at over $3 billion, with production at the Holly Springs large-scale facility."
- [confirms] Pharm Edaily (KO, news, published 2024-11-08) https://pharm.edaily.co.kr/news/read?newsId=01918806638856120: "Fujifilm invests an additional ~JPY180B (KRW1.6T) to expand its North Carolina bio-CDMO plant, adding antibody capacity."

### 의료기관 (내시경·CT/MRI·IVD) (high)
- note: Healthcare segment medical-systems business supplies endoscopes, CT/MRI and in-vitro diagnostics (IVD) to hospitals and clinics. Segment revenue JPY1,022.6B (+4.9%); strong endoscope, CT/MRI and IVD sales offset declining medical-film demand.
- [confirms] FUJIFILM Holdings (EN, filing, published 2025-05-02) https://ir.fujifilm.com/en/investors/ir-news/auto_20250502530287/pdfFile.pdf: "Healthcare segment revenue JPY1,022.6B (+4.9%); medical systems revenue increased on strong sales of endoscopes, CT/MRI systems and IVD products."

### 바이오젠 (mid)  → /biogen.md
- note: Fujifilm Holdings, through its group, acquired Biogen's Hillerød site in Denmark and entered manufacturing-services agreements covering commercial biologics including TYSABRI, with the individual manufacturing consideration undisclosed.
- [confirms] Yonhap News Agency (KO, news, published 2019-03-13) https://www.yna.co.kr/view/AKR20190312160400017: "Biogen sold the Hillerød facility to Fujifilm for $890 million, and the existing manufacturing contracts transferred to Fujifilm."
- [confirms] Biogen Investor Relations (EN, ir, published 2019-03-12) https://investors.biogen.com/node/20891: "Fujifilm will use the Hillerød site to produce commercial products for Biogen, such as TYSABRI."

Reverse side: https://valuechain.wiki/fujifilm-holdings/suppliers.md · Ripple: https://valuechain.wiki/fujifilm-holdings/ripple.md

---
Full node: https://valuechain.wiki/fujifilm-holdings.md · JSON: https://valuechain.wiki/fujifilm-holdings.json